A Case of Refractory Cutaneous Sarcoidosis Successfully Treated with Infliximab
Main Article Content
Keywords
Refractory cutaneous sarcoidosis, infliximab, hair regrowth
Abstract
Sarcoidosis is an inflammatory granulomatous disease affecting multiple organs with cutaneous sarcoidosis occurring in 25% of patients. There are several treatment options available, but alternative therapies should be considered in patients with refractory disease to standard intervention. Though they are not been FDA-approved for sarcoidosis, TNF-a inhibitors have demonstrated significant therapeutic intervention targeting proinflammatory cytokines involves in pathogenesis of sarcoidosis. Herein, we present a case of refractory cutaneous sarcoidosis successfully treated with infliximab therapy with significant hair regrowth on the scalp.
References
2. Wanat, K.A. and Rosenbach, M., 2015. Cutaneous sarcoidosis. Clinics in chest medicine, 36(4), pp.685-702.
3. Noor, A. and Knox, K.S., 2007. Immunopathogenesis of sarcoidosis. Clinics in dermatology, 25(3), pp.250-258.
4. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med. 2006;100(11):2053-2059. doi:10.1016/j.rmed.2006.02.017.
5. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest. 2003;124(5):2028-2031. doi:10.1378/chest.124.5.2028.
6. Udkoff, J. and Cohen, P.R., 2016. Severe infliximab-induced alopecia and scalp psoriasis in a woman with Crohn’s disease: dramatic improvement after drug discontinuation and treatment with adjuvant systemic and topical therapies. Dermatology and Therapy, 6, pp.689-695.
7. Lindsey, S.F. and Tosti, A., 2013. Hair loss induced by tumor necrosis factor alpha inhibitors. J Clin Investigat Dermatol, 1(1), p.6.
8. Philpott, M.P., Sanders, D.A., Bowen, J. and Kealey, T., 1996. Effects of interleukins, colony‐stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin‐1 and tumour necrosis factor‐α in alopecia areata. British journal of dermatology, 135(6), pp.942-948.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.
Roudha Jassim Al-Dehneem, Mount Sinai Hospital
Roudha Al-Dehneem, MD,MSc
Associate consultant dermatologist
Fellow at Mount sinai hospital, New York